Rare(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Unknown frequency(cannot be estimated from available data)
Appearance of blisters on the skin, mouth, eyes, or genitals – may be signs of "toxic epidermal necrolysis" or "Stevens-Johnson syndrome" or drug reaction with eosinophilia and systemic symptoms (DRESS). DRESSappears initially as symptoms similar to the flu and a rash on the face, followed by a prolonged rash with high fever, elevated liver enzymes observed in blood tests, and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes.
Inform your doctor or nurse immediately if you experience any of the side effects mentioned above.
Inform your doctor or nurse immediately if you experience any of the following severe side effects – you may need urgent medical treatment:
Rare(may affect up to 1 in 100 people)
Unknown frequency(cannot be estimated from available data)
Inform your doctor or nurse immediately if you experience any of the side effects mentioned above.
Other side effects
Talk to your doctor, pharmacist, or nurse if you experience any of the following side effects:
Common(may affect up to 1 in 10 people)
Rare(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Unknown frequency(cannot be estimated from available data)
Reporting side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly throughthe Spanish System for Pharmacovigilance of Medicines for human use:www.notificaRAM.es.By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging and the vial label after CAD. The expiration date is the last day of the month indicated.
For powder and solvent:
Store below 25°C. Store the packaging in the outer packaging to protect it from light.
For single use only.
Discard any unused solution.
The information about conservation and the time to use Teicoplanin Noridem once it is reconstituted and ready for use is detailed in “Practical information for healthcare professionals on the preparation and manipulation of Teicoplanin Noridem”.
Composition of Teicoplanin Noridem
Each mL of reconstituted solution contains 66.7 mg of teicoplanin.
Appearance of the product and contents of the package
Teicoplanin Noridem is a powder and solvent for injectable solution and for infusion or oral solution.
The powder is a white to off-white powder. The solvent is a transparent and colorless solution.
The powder is packaged:
Presentations: 1 vial of 200 mg + 1 ampoule of 3 mL of solvent
10 vials of 200 mg + 10 ampoules of 3 mL of solvent
Only some package sizes may be commercially available.
Marketing authorization holder and responsible manufacturer
Marketing authorization holder:Noridem Enterprises Ltd., Evagorou & Makariou, Mitsi Building 3, Office 115, 1065 Nicosia, Cyprus.
Responsible manufacturer:DEMO S.A., 21stkm National Road Athens-Lamia, 14568 Krioneri, Attica, Greece.
This medicinal product is authorized in the member states of the European Economic Area with the following names:
United Kingdom | Teicoplanin 200 mg Powder and Solvent for Solution for injection/infusion or oral solution |
Austria | Teicoplanin Noridem 200 mg Pulver und Lösungsmittel zur Herstellung einer Injektion-/ Infusionslösung oder einer Lösung zum Einnehmen |
Germany | Teicoplanin Noridem 200 mg Pulver und Lösungsmittel zur Herstellung einer Injektions-/ Infusionslösung oder einer Lösung zum Einnehmen |
Greece | TeicoplaninNoridem200mgΚ?νις και διαλ?της για παρασκευ? ενεσ?μου διαλ?ματος ? διαλ?ματος προς ?γχυση |
Spain | Teicoplanin Noridem 200 mg Polvo y disolvente para solución inyectable y para perfusion EFG |
Ireland | Teicoplanin 200 mg Powder and Solvent for Solution for injection/infusion or oral solution |
Last review date of this leaflet: 10/2022.
This information is intended solely for healthcare professionals:
Practical information for healthcare professionals on the preparation and handling of Teicoplanin Noridem. This medicinal product is for single use only.Dispose of any unused solution. The reconstitution/dilution must be performed in aseptic conditions. Before administration, the solution must be visually inspected for particles and color change. Only use the solution if it is transparent and free of particles. Administration form Teicoplanin must be administered intravenously or intramuscularly.The intravenous injection can be administeredas a bolus over 3-5 minutes or by infusion over 30 minutes. Only by infusion in newborn babies. For diarrhea and colitis associated withClostridioides difficileinfection, use the oral route. Preparation of the reconstituted solution: The solution is reconstituted by adding the entire contents of the solvent provided to the 200 mg and 400 mg powder vials. Water is added slowly to the vial, which must be rotated until all the powder is dissolved to prevent foam formation. If foam develops, allow the solution to stand for approximately 15 minutes for the foam to dissipate. Only use transparent and yellowish solutions. The reconstituted solutions will contain 200 mg of teicoplanin in 3.0 mL. The final solution is isotonic with plasma and has a pH of 7.2-7.8.
The reconstituted solution can be administered directly or alternatively diluted, or administered orally. Preparation of the diluted solution before infusion Teicoplanin Noridem can be administered in the following infusion solutions:
Valid period of the reconstituted solution: Chemical and physical stability has been demonstrated in use of the reconstituted solution with water for injection over 24 hours between 2°C and 8°C. From a microbiological point of view, the product must be used immediately. If not used immediately, the times and conditions of storage in use are the responsibility of the user and should not normally exceed 24 hours between 2°C and 8°C, unless reconstitution has been performed in controlled and validated aseptic conditions. Valid period of the diluted medication Chemical and physical stability in use of the reconstituted solution prepared as recommended has been demonstrated over 24 hours between 2 and 8°C. From a microbiological point of view, the medication must be used immediately. If not used immediately, the times and conditions of storage in use are the responsibility of the user and should not normally exceed 24 hours between 2 and 8°C, unless reconstitution/dilution has been performed in controlled and validated aseptic conditions. Elimination The disposal of unused medication and all materials that have come into contact with it will be carried out in accordance with local regulations. |
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.